DVP EU markets and sells Dechra's products throughout Europe and exports to over 40 countries. The business has an operating board of eight senior managers, and is managed from Den Bosch, the Netherlands, Sansaw, UK, and Uldum, Denmark. In total, DVP EU employs 386 people. Inventory is managed through a central distribution centre in Uldum.
DVP EU has sales operations in 15 countries: Austria, Belgium, Denmark, Finland, France, Germany, Ireland, Italy, the Netherlands, Norway, Poland, Portugal, Spain, Sweden and the UK, each run by a Country Manager. DVP EU also exports to other European countries as well as other territories including Australia, Brazil, the Middle East and the Far East.
The key products in the DVP EU portfolio are predominantly Companion Animal Products (CAP), Equine medicines and Food producing Animal Products (FAP). DVP EU also markets a range of specialist, therapeutic and maintenance pet diets, branded Specific™.
In October 2015, Dechra acquired Genera d.d., which has sales operations in four markets, namely Croatia, Bosnia-Herzegovina, Serbia and Slovenia. Genera markets a range of FAP, agrochemicals and feed additives. It also develops and sells a range of poultry vaccines. Genera employs 120 people (excluding Manufacturing and Product Development and Regulatory Affairs (PDRA)).
* Includes Melbourne, Florida and Brovel, Mexico City
DPM produces the majority of Dechra's pharmaceuticals and manufactures for third parties on a contract basis. The objectives are to produce Dechra's product range efficiently to the highest quality standards, to maintain a reliable supply chain and to contribute profit to the business through third party manufacturing.
The site at Skipton employs 232 people. It offers a comprehensive range of manufacturing and packing services, principally for CAP. It is dual-licensed to produce both veterinary and human products. The site includes Pharmaceutical Development, Quality Control (QC) and Stability Testing and Validation Laboratories.
Bladel, the Netherlands
The site at Bladel employs 126 people and manufactures products for food producing animals in large-scale batches. It also has an aseptic manufacturing facility to produce sterile injections, an important competence in DPM's manufacturing portfolio. As in Skipton, the site includes QC and Development Laboratories.
The Genera site in Zagreb, Croatia employs 97 people. It has a poultry vaccine manufacturing facility, a liquids facility and a solid dose suite which is EU approved. In addition, it has a feed additive facility which is solely used for third party manufacturing.